Randy R. Robinson

发表

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Till Sprenger, Gavin Giovannoni, Eva Kubala Havrdova, 2020, Journal of Neurology.

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

T. Waldmann, R. Nussenblatt, S. Yeh, 2008, Journal of autoimmunity.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

T. Waldmann, Darby J. S. Thompson, S. Srivastava, 2003, Journal of autoimmunity.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Gavin Giovannoni, Xavier Montalban, Ernst-Wilhelm Radue, 2013, The Lancet.

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

X. Montalban, E. Radue, R. Gold, 2012 .

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

D. Arnold, L. Kappos, S. Cohan, 2021, Therapeutic advances in neurological disorders.

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.

Kimberly Umans, J. Elkins, Randy R. Robinson, 2017, International journal of MS care.

Long-Term Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: 3 Year Results from the SELECTED Extension Study (P7.226)

X. Montalban, E. Radue, R. Gold, 2015 .

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

K. Kelly, A. Lassman, K. Papadopoulos, 2022, Neuro-oncology advances.